Aktienanalyse zu Olema Pharmaceuticals Inc (OLMA)OLMAOlema Pharmaceuticals Inc

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. It is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a novel, orally available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD). It is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Its second product candidate in clinical development, called OP-3136, is a novel, orally available small molecule that potently and selectively inhibits KAT6, an epigenetic target that is dysregulated in breast and other cancers. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Currently, Olema Pharmaceuticals Inc (OLMA) is not a good buy. The stock is trading at $7.82, significantly below its analyst price targets, which range from $20 to $59. However, the stock has a very low RSI of 14.106, indicating it is oversold, but the overall trend is negative with a year-to-date change of -69.07%. The main risk is its ongoing losses, with a net income of -$63.2 million reported for Q2 2026, which raises concerns about its financial sustainability.